Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (2)

Trial Status

Active Not Recruiting2
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04065776Not ApplicableActive Not Recruiting

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

NCT01837862Phase 1Active Not RecruitingPrimary

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01884740Phase 1Terminated

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Showing all 3 trials

Research Network

Activity Timeline